Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold initiates Phase I/II myeloma trial
TH-302 is a hypoxia-targeted drug where as Bortezomib is approved for the treatment of multiple myeloma, a hematologic cancer that develops in the bone marrow. The primary objectives
TH-302 is a hypoxia-targeted drug where as Bortezomib is approved for the treatment of multiple myeloma, a hematologic cancer that develops in the bone marrow. The primary objectives
The new database is expected to enable the pharmaceutical company to deliver improved stakeholder understanding and relationship-building, and to gain access to the solution’s full panel of European
As per the agreement signed in the first quarter of 2012, the global health brand will deploy the CallidusCloud solutions with the company Salesforce.com CRM solution to drive
The randomized double-blind placebo-controlled multi-center Phase II clinical trial enrolled a total of 164 patients to investigate the efficacy and safety of Trimesta. Synthetic Biologics chief executive officer
The study will evaluate the safety and immunogenicity of ONT-10 in patients with cancers which commonly express MUC1, such as breast, non-small cell lung, ovarian, colorectal, prostate, pancreatic,
The company received FDA approval for Natazia in May 2010 for the prevention of pregnancy. The contraceptive efficacy of Natazia has not been evaluated in women with a
Escitalopram Oxalate Tablet is the generic version of Forest Laboratories’ depression and generalized anxiety disorder treatment tablets. Teva has received a 180-day period of marketing exclusivity as it
Omnaris nasal spray is indicated for the treatment of seasonal allergic rhinitis (SAR) nasal symptoms and for perennial allergic rhinitis (PAR) nasal symptoms. The corticosteroid is composed of
The drug discovery collaboration will utilize Numerate’s in silico drug design technology to generate drug leads for an undisclosed cardiovascular disease target. The platform will feature a set
The liposomal delivery technology is used in the development and commercialization of DNAi-based therapeutics. As per the agreement, Marina could receive up to $14m for each gene target